A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer
Conclusions: This phase II study showed a high objective response rate and long survival. Irinotecan monotherapy schedule used was well tolerated, and could be an active treatment option for these patients.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Hematology | Lung Cancer | Small Cell Lung Cancer | Study | Thrombocytopenia | Toxicology